Kari Alitalo on Michael’s Domain

Inauguration of the new professors

Thu, 28 May 2026 00:00:00 +0000

We - the new professors in the Faculty of Pharmacy at the University of Helsinki - gave our inaugural lectures yesterday!

Billion-dollar gamble

Fri, 28 Feb 2025 00:00:00 +0000

Last December, Forbes published a feature article about Megan Baldwin’s work to improve the antiangiogenic treatment of eye diseases. I hope she wins her billion-dollar gamble not only because the drug in question was invented here at the University of Helsinki. The drug is called OPT-302 or with its INN name sozinibercept. The patent lists Kari Alitalo and me as the inventors. The drug was initially designed (under the name VGX-300) for cancer treatment, but - perhaps luckily - never really took off as such because it inhibits not only VEGF-D but also VEGF-C, which is needed in the body’s immune response against the cancer. So far, nobody has been able to separate the prometastatic and the proimmunogenic propeties of VEGF-C.

Cutting-edge vascular biology continues at the Wihuri Research Institute

Wed, 10 May 2023 00:00:00 +0000

Taija Mäkinen has been appointed to become the Wihuri Research Institute (WRI) Director starting in 2024. Like the current director Kari Alitalo , Taija has outstanding expertise in lymphatic vascular biology. Taija is currently doing research in Sweden at Uppsala University . With her contributions, she has revolutionized our understanding of how lymphatic vessels form and grow ( 10.1016/j.celrep.2015.02.026 , 10.1161/CIRCRESAHA.116.306170 ).The Wihuri Research Institute , located at Biomedicum Helsinki, was founded and is funded by the Jenny and Antti Wihuri Foundation . It focuses on cardiovascular and vascular biology. This research is essential for the development of new treatments for heart disease. However, blood and lymphatic vessels penetrate nearly all body organs and play a role in almost all diseases, including inflammatory and infectious diseases, neurodegenerative diseases, cancer, and vascular malformations or hypoplasia. Therefore, the research done at the WRI opens avenues for treating many diseases beyond heart disease. The Board of Trustees of the Jenny and Antti Wihuri Foundation has made an excellent choice, even though I am biased for many reasons. I do similar research, and I worked in the same lab as Taija during our Ph.D. education. Unnecessary to mention that Taija graduated faster than I did …

Lymphatics as the origin of the fish secondary vascular system

Thu, 26 May 2022 00:00:00 +0000

In zebrafish, the blood vessels of the anal fin develop from lymphatics by transdifferentiation. Karina Yaniv presented unorthodox, but very compelling data supporting this conclusion last September at the Kloster Seeon Angiogenesis meeting .Now her paper has been published in Nature .

We got featured by Circulation!

Mon, 12 May 2014 00:00:00 +0000

A Nobel Prize for angiogenesis research?

Sun, 27 Oct 2013 00:00:00 +0000

In 2008, during a dinner in Stockholm (when I participated in the Novo Nordisk Foundation 8th Annual Conference on Vascular Biology in Diabetes Complications) I proposed to Christer Betsholtz to award the Nobel Prize to the world-wide community of postdocs, which are the unsung heroes of today’s research. But the Statutes of the Nobel Foundation forbid to award the price to more than three people. However, statutes can be changed and the Nobel Foundation did exactly that 40 years ago when they stopped awarding the price to dead people. And in this changing world, less and less discoveries and inventions are made by individuals. But here’s my newest proposal, which adheres to the rule of maximally three: Kari Alitalo is probably the only Nobel Prize worthy researcher in the country where I work (Finland). Seriously: after Judah Folkman has passed away, there are not many options to award the prize to somebody from the angiogenesis field. Judah Folkman was the father of the hypothesis, that all tumors should be treatable by anti-angiogenesis ( Folkman J. Tumor Angiogenesis: Therapeutic Implications. New England Journal of Medicine. 1971;285(21):1182–6 ). The Nobel Prize committee missed that chance. And because the field has already significantly contributed to the treatment of cancer (and arguably will still contribute much), it is not so far off to think of a shared prize for the discoverers of the VEGFs. VEGF was discovered more or less independently by several research groups around 25 years ago, among them Napoleone Ferrara ’s and Harold Dvorak ’s. Most notably, Ferrara’s group at Genentech continued the research most successfully until today resulting in the first antiangiogenic cancer drug in 2004. While the discovery of VEGF and the resulting angiogenesis research was not dependent on any single lab, the lymphangiogenesis field was essentially single-handedly re-invented and brought into the molecular era by Kari Alitalo in the years following 1995 - after it had become senile and was lingering without any significant progress since the 1960s. A shared prize to Ferrara, Dvorak and Alitalo? There is an anti-VEGF-A cancer drug on the market and the only thing lacking is a successful anti- or pro-VEGF-C drug. Both are in clinical trials as of this writing ( anti-VEGF-C , pro-VEGF-C ).

Cyclical PhD production

Tue, 11 Jun 2013 00:00:00 +0000

I was wondering why recently nobody graduated with a PhD from our lab. My first (and wrong) conclusion was, that our lab is not as productive anymore as it used to be. When I looked at the data carefully I discovered an interesting phenomenon: The PhD production rate in our lab follows a 5-6 year cycle. And lo and behold: The cycle is about to peak again in 2013/2014, which is exactly what I expect to happen as many of our PhD students are about to finnish this or next year. I wonder whether this is specific for Kari Alitalo’s lab or whether this a general phenomenon. In any case I am looking forward to all those parties (“karonkka”) that lie ahead.The figure above shows the number of PhDs received any given year that were supervised by Kari Alitalo averaged over a window of one or three years. Shared supervision was counted as 0.5.

The Molecular/Cancer Biology Lab 2008

Sat, 11 Jul 2009 00:00:00 +0000

The Molecular/Cancer Biology Lab 2008

Mon, 11 May 2009 00:00:00 +0000

The Molecular/Cancer Biology Lab 10 years ago

Tue, 05 May 2009 00:00:00 +0000

I cleaned my computer files and I found this historical photo collage…

And here is another historical document. It’s an article about the Alitalo laboratory in the “Yliopisto” magazine from September 2002:

Unlocking the drains

Mon, 01 Aug 2005 00:00:00 +0000

Nice article by Phyllida Brown in Nature describing the discovery of the VEGF-C/VEGFR-3 signalling axis, and how research on the lymphatic system turned into a hot topic: https://www.nature.com/articles/436456a .

Michael Jeltsch’s PhD thesis

Mon, 25 Nov 2002 00:00:00 +0000

My doctoral thesis has been published: Michael Jeltsch VEGFR-3 Ligands and Lymphangiogenesis, Helsinki 2002. The public defence will take place in Biomedicum, Helsinki, on November 29th, 2002.

Projects in the Molecular/Cancer Biology Laboratory

Fri, 31 Dec 1999 00:00:00 +0000

Available Downloads

Get the poster in PDF format.

Download PDF